Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3718596,initial t1/2,"This radioactivity disappears quickly from plasma (initial t1/2 = 13 min, terminal t1/2 = 118 min).",Pharmacokinetics of glucosamine in the dog and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718596/),min,13,215,DB01296,Glucosamine
,3718596,terminal t1/2,"This radioactivity disappears quickly from plasma (initial t1/2 = 13 min, terminal t1/2 = 118 min).",Pharmacokinetics of glucosamine in the dog and in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718596/),min,118,216,DB01296,Glucosamine
,3718596,t1/2,"The protein-incorporated radioactivity is found already 20-30 min after i.v. administration, reaches a peak after 8 h and then slowly disappears, with a t1/2 = 2.9 days.",Pharmacokinetics of glucosamine in the dog and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718596/),d,2.9,217,DB01296,Glucosamine
,25802209,run time,"The chromatographic separation was achieved on a Waters ACQUITY HSS Cyano column using a mixture of acetonitrile/2 mM ammonium acetate solution containing 0.03% formic acid (80:20, v/v) as the mobile phase with a very short run time of 1.5 min.",Sensitive and rapid analytical method for the quantification of glucosamine in human plasma by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25802209/),min,1.5,3284,DB01296,Glucosamine
,16168682,elimination half-life,Glucosamine elimination half-life was only tentatively estimated to average 15 h.,Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168682/),h,15,8857,DB01296,Glucosamine
,6422479,half-disappearance time,"After intravenous administration, plasma radioactivity declined in the first 30 min, then increased, reaching a peak at the 2nd hour, and disappeared, with a half-disappearance time of 28 hours.","Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6422479/),h,28,16212,DB01296,Glucosamine
,6422479,Faecal excretion,Faecal excretion was small (2% of the administered dose).,"Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6422479/),,2,16213,DB01296,Glucosamine
,6422479,excretion,"There was only small faecal excretion, showing an almost complete bioavailability of glucosamine given orally, and the large excretion with the CO2 (82%) showed that glucosamine is to a large extent broken down to smaller fragments.","Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6422479/),,82,16214,DB01296,Glucosamine
,24375187,Minimum effective dose,"Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans.",Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375187/),[kg·mg] / [day],40,24604,DB01296,Glucosamine
,24375187,maximum plasma concentration,"Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans.",Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375187/),[mg] / [l],1.37,24605,DB01296,Glucosamine
,24375187,maximum plasma concentration,"Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans.",Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375187/),[mg] / [l],1.6,24606,DB01296,Glucosamine
,12207870,flow rate,"Analysis was accomplished by injection of 0.1 mL of the sample solution into an isocratic HPLC system consisting of a C18 column, a mobile phase of acetonitrile: water: acetic acid: triethylamine (4.5: 95.5:0.1:0.05), a flow rate of 0.9 mL/min, and a UV detector set at 254 nm.",High performance liquid chromatographic determination of glucosamine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207870/),[ml] / [min],0.9,40358,DB01296,Glucosamine
,27474667,critical micelle concentration (CMC),"The critical micelle concentration (CMC) decreased with an increasing substitution of TS on LMW Cmc, which ranged from 7.94×10(-8) to 1.58×10(-6)g/mL.","Polymeric micelles of amphiphilic graft copolymer of α-tocopherol succinate-g-carboxymethyl chitosan for tamoxifen delivery: Synthesis, characterization and in vivo pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474667/),[g] / [ml],7.94×10(-8),52011,DB01296,Glucosamine
,27474667,critical micelle concentration (CMC),"The critical micelle concentration (CMC) decreased with an increasing substitution of TS on LMW Cmc, which ranged from 7.94×10(-8) to 1.58×10(-6)g/mL.","Polymeric micelles of amphiphilic graft copolymer of α-tocopherol succinate-g-carboxymethyl chitosan for tamoxifen delivery: Synthesis, characterization and in vivo pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474667/),[g] / [ml],1.58×10(-6),52012,DB01296,Glucosamine
,16821643,linear dynamic,The assay exhibited a linear dynamic range of 100-6000 ng/mL for miglitol in human plasma.,Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),[ng] / [ml],100-6000,52454,DB01296,Glucosamine
,16821643,absolute recoveries,"The average absolute recoveries of miglitol and the IS from spiked plasma samples were 40.5 +/- 2.7 and 47.1 +/- 2.9 %, respectively.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),%,40.5,52455,DB01296,Glucosamine
,16821643,absolute recoveries,"The average absolute recoveries of miglitol and the IS from spiked plasma samples were 40.5 +/- 2.7 and 47.1 +/- 2.9 %, respectively.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),%,47.1,52456,DB01296,Glucosamine
,16821643,run time,A run time of 2.5 min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),min,2.5,52457,DB01296,Glucosamine
,16821643,observed maximum plasma concentration (Cmax),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),[ng] / [ml],1740,52458,DB01296,Glucosamine
,16821643,time to observed maximum plasma concentration (tmax),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),h,3.5,52459,DB01296,Glucosamine
,16821643,elimination half-life (t(1/2)),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),h,2.5,52460,DB01296,Glucosamine
,17207418,terminal half-life,"Following i.v. administration, the terminal half-life was 0.29 -/+ 0.06 h, volume of distribution at steady state was 2.1 -/+ 0.26 L/kg and total body clearance was 5.23 -/+ 1.44 L/h/kg.",Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),h,0.29,55009,DB01296,Glucosamine
,17207418,volume of distribution at steady state,"Following i.v. administration, the terminal half-life was 0.29 -/+ 0.06 h, volume of distribution at steady state was 2.1 -/+ 0.26 L/kg and total body clearance was 5.23 -/+ 1.44 L/h/kg.",Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),[l] / [kg],2.1,55010,DB01296,Glucosamine
,17207418,total body clearance,"Following i.v. administration, the terminal half-life was 0.29 -/+ 0.06 h, volume of distribution at steady state was 2.1 -/+ 0.26 L/kg and total body clearance was 5.23 -/+ 1.44 L/h/kg.",Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),[l] / [h·kg],5.23,55011,DB01296,Glucosamine
less,17207418,Bioavailability,Bioavailability was less than 17% and 100% following oral and i.p. doses respectively.,Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),%,17,55012,DB01296,Glucosamine
,17207418,Bioavailability,Bioavailability was less than 17% and 100% following oral and i.p. doses respectively.,Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),%,100,55013,DB01296,Glucosamine
,17207418,Tmax,"GLcNBu was rapidly absorbed after oral doses (Tmax, 29-40 min).",Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207418/),min,29-40,55014,DB01296,Glucosamine
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],879.6,58814,DB01296,Glucosamine
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],486.8,58815,DB01296,Glucosamine
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],281.5,58816,DB01296,Glucosamine
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],1123.9,58817,DB01296,Glucosamine
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],114.7,58818,DB01296,Glucosamine
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],997.6,58819,DB01296,Glucosamine
,9239452,apparent elimination half-lives,Miglitol is rapidly eliminated from plasma with apparent elimination half-lives of 0.4-1.8 h.,"Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239452/),h,0.4-1.8,59466,DB01296,Glucosamine
,9239452,volumes of distribution,The volumes of distribution are low (0.3-0.8 l/ kg).,"Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239452/),[l] / [kg],0.3-0.8,59467,DB01296,Glucosamine
,9239452,half-lives,At this very low concentration level a terminal elimination phase of radioactivity characterized by half-lives of 50-110 h was observed giving rise to a slight tendency for accumulation (accumulation factors < 6) following repeated administration to rats.,"Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239452/),h,50-110,59468,DB01296,Glucosamine
<,9239452,accumulation factors,At this very low concentration level a terminal elimination phase of radioactivity characterized by half-lives of 50-110 h was observed giving rise to a slight tendency for accumulation (accumulation factors < 6) following repeated administration to rats.,"Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239452/),,6,59469,DB01296,Glucosamine
,29403716,flow rate,"Chromatographic separation was performed on a Phenomenex ODS column (150 mm×4.6 mm, 5 μm) using linear gradient elution by a mobile phase consisting of methanol (A), and an aqueous solution containing 0.2% ammonium acetate and 0.1% formic acid (B) at a flow rate of 1 mL/min.",Precolumn derivatization LC-MS/MS method for the determination and pharmacokinetic study of glucosamine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403716/),[ml] / [min],1,61707,DB01296,Glucosamine
,22791244,Cmax,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [ml],907.01,79045,DB01296,Glucosamine
,22791244,Cmax,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [ml],944.40,79046,DB01296,Glucosamine
,22791244,Tmax,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),h,3.03,79047,DB01296,Glucosamine
,22791244,Tmax,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),h,3.30,79048,DB01296,Glucosamine
,22791244,AUC0-12,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [h·ml],2891.41,79049,DB01296,Glucosamine
,22791244,AUC0-12,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [h·ml],2889.69,79050,DB01296,Glucosamine
,22791244,AUC0-∞,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [h·ml],3029.90,79051,DB01296,Glucosamine
,22791244,AUC0-∞,"The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h.",Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),[ng] / [h·ml],3091.87,79052,DB01296,Glucosamine
,22791244,t1/2,The mean (SD) t1/2 was 1.10 (0.52) hours for the test formulation and 1.50 (1.17) hours for the reference formulation.,Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),h,1.10,79053,DB01296,Glucosamine
,22791244,t1/2,The mean (SD) t1/2 was 1.10 (0.52) hours for the test formulation and 1.50 (1.17) hours for the reference formulation.,Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),h,1.50,79054,DB01296,Glucosamine
,22791244,relative bioavailability,The relative bioavailability of the test formulation was 98.3% assessed by AUC0-12.,Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791244/),%,98.3,79055,DB01296,Glucosamine
higher,22031460,Recovery rates,Recovery rates higher than 90% were obtained for both glucosamine and internal standard.,Quantitation of glucosamine sulfate in plasma by HPLC-MS/MS after administration of powder for oral solution formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031460/),%,90,82856,DB01296,Glucosamine
,18814196,flow rate,"An amino acid analysis column (3.9 x 150 mm, 4 microm) was applied, with 140 mM sodium acetate buffer (pH = 5.25) and acetonitrile as mobile phase at a flow rate of 1 mL/min.",Optimizing high-performance liquid chromatography method for quantification of glucosamine using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate derivatization in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814196/),[ml] / [min],1,85328,DB01296,Glucosamine
,18814196,limit of detection,The limit of detection was 30 ng/mL.,Optimizing high-performance liquid chromatography method for quantification of glucosamine using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate derivatization in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814196/),[ng] / [ml],30,85329,DB01296,Glucosamine
more,18814196,Extraction recoveries,Extraction recoveries of glucosamine in plasma were more than 90%.,Optimizing high-performance liquid chromatography method for quantification of glucosamine using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate derivatization in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814196/),%,90,85330,DB01296,Glucosamine
,23830943,relative bioavailabilities,"Further pharmacokinetic studies in beagle dogs demonstrated that QD-Glu solution and QD-Glu tablet showed much higher relative bioavailabilities of 313% and 186%, when comparing with Wellesse™ solution and Voltaflex™ tablet, respectively.",Bioavailability enhancement of glucosamine hydrochloride by chitosan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830943/),%,313,99198,DB01296,Glucosamine
,23830943,relative bioavailabilities,"Further pharmacokinetic studies in beagle dogs demonstrated that QD-Glu solution and QD-Glu tablet showed much higher relative bioavailabilities of 313% and 186%, when comparing with Wellesse™ solution and Voltaflex™ tablet, respectively.",Bioavailability enhancement of glucosamine hydrochloride by chitosan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830943/),%,186,99199,DB01296,Glucosamine
,28502673,bioavailability,"Propranolol (PROP) undergoes extensive first-pass metabolism by the liver resulting in a relatively low bioavailability (13-23%); thus, multiple oral doses are required to achieve therapeutic effect.",Glucosamine modulates propranolol pharmacokinetics via intestinal permeability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28502673/),%,13-23,111481,DB01296,Glucosamine
,16931183,recovery,"The precision (R.S.D.) and the accuracy (bias) of the method at the limit of quantification were 13.8 and 4.0%, respectively, and the mean recovery of glucosamine at three concentration levels was 101.6+/-5.7%.",Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931183/),%,101.6,113162,DB01296,Glucosamine
,15641100,maximum concentration,The maximum concentration of glucosamine in serum reached approximately 300 muM ( approximately 50 microg/ml) following IV dosing and approximately 6 microM (approximately 1 microg/ml) following NG dosing.,Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),muM,300,114537,DB01296,Glucosamine
,15641100,maximum concentration,The maximum concentration of glucosamine in serum reached approximately 300 muM ( approximately 50 microg/ml) following IV dosing and approximately 6 microM (approximately 1 microg/ml) following NG dosing.,Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),[μg] / [ml],50,114538,DB01296,Glucosamine
,15641100,maximum concentration,The maximum concentration of glucosamine in serum reached approximately 300 muM ( approximately 50 microg/ml) following IV dosing and approximately 6 microM (approximately 1 microg/ml) following NG dosing.,Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),μM,6,114539,DB01296,Glucosamine
,15641100,maximum concentration,The maximum concentration of glucosamine in serum reached approximately 300 muM ( approximately 50 microg/ml) following IV dosing and approximately 6 microM (approximately 1 microg/ml) following NG dosing.,Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),[μg] / [ml],1,114540,DB01296,Glucosamine
,15641100,Synovial fluid concentrations,"Synovial fluid concentrations reached 9-15 microM with IV dosing and 0.3-0.7 microM with NG dosing, and remained elevated (range 0.1-0.7 microM) in most animals even at 12 hours after dosing.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),μM,9-15,114541,DB01296,Glucosamine
,15641100,Synovial fluid concentrations,"Synovial fluid concentrations reached 9-15 microM with IV dosing and 0.3-0.7 microM with NG dosing, and remained elevated (range 0.1-0.7 microM) in most animals even at 12 hours after dosing.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),μM,0.3-0.7,114542,DB01296,Glucosamine
,15641100,serum maximal concentration,"Following NG dosing, the median serum maximal concentration of 6.1 microM (range 4.38-7.58) was attained between 30 minutes and 4 hours postdose.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),μM,6.1,114543,DB01296,Glucosamine
,15641100,apparent volume of distribution,"The mean apparent volume of distribution was 15.4 liters/kg, the mean bioavailability was 5.9%, and the mean elimination half-life was 2.82 hours.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),[l] / [kg],15.4,114544,DB01296,Glucosamine
,15641100,bioavailability,"The mean apparent volume of distribution was 15.4 liters/kg, the mean bioavailability was 5.9%, and the mean elimination half-life was 2.82 hours.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),%,5.9,114545,DB01296,Glucosamine
,15641100,elimination half-life,"The mean apparent volume of distribution was 15.4 liters/kg, the mean bioavailability was 5.9%, and the mean elimination half-life was 2.82 hours.",Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641100/),h,2.82,114546,DB01296,Glucosamine
,20408501,Protein binding,"Protein binding of [14C]glucosamine (400, 1000 and 4000 ng/ml) was evaluated in human and mouse plasma and in human synovial fluid.",Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408501/),[ng] / [ml],400,119891,DB01296,Glucosamine
,20408501,Protein binding,"Protein binding of [14C]glucosamine (400, 1000 and 4000 ng/ml) was evaluated in human and mouse plasma and in human synovial fluid.",Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408501/),[ng] / [ml],1000,119892,DB01296,Glucosamine
,20408501,Protein binding,"Protein binding of [14C]glucosamine (400, 1000 and 4000 ng/ml) was evaluated in human and mouse plasma and in human synovial fluid.",Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408501/),[ng] / [ml],4000,119893,DB01296,Glucosamine
,28820428,Tmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),h,2,120987,DB01296,Glucosamine
,28820428,Cmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),[μg] / [ml],9.69,120988,DB01296,Glucosamine
,32576047,bioavailability,"Although many basic and clinical studies have shown that glucosamine (GlcN) improves osteoarthritis, it has not been widely used in the clinic because its bioavailability is only 6%.",Absorption of glucosamine is improved by considering circadian rhythm and feeding time in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32576047/),%,6,127538,DB01296,Glucosamine
,25739190,relative bioavailability,On the base on the pharmacokinetic profiles data of glucosamine in rat blood plasma with daily administration in 3 times a day for 1 week by cream Hondroxid Maximum 400 mg/kg and the single injection solution of 4% Glucosamine sulfate 400 mg/kg was found that the relative bioavailability was 61.6%.,"[Relative bioavailability of glucosamine after oral, intramuscular and transdermal administration of hondroxid maximum preparation in experiment]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739190/),%,61.6,131097,DB01296,Glucosamine
,25739190,penetration rate,"Calculated penetration rate of glucosamine in the plasma through the rats skin in 4 hours, equal to 26.9 μg/cm2 x h, and the penetration of glucosamine through the skin into the plasma after a single dose of cream in 4 hours was 4.12%.","[Relative bioavailability of glucosamine after oral, intramuscular and transdermal administration of hondroxid maximum preparation in experiment]. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739190/),[μg] / [cm2·h],26.9,131098,DB01296,Glucosamine
,25739190,penetration,"Calculated penetration rate of glucosamine in the plasma through the rats skin in 4 hours, equal to 26.9 μg/cm2 x h, and the penetration of glucosamine through the skin into the plasma after a single dose of cream in 4 hours was 4.12%.","[Relative bioavailability of glucosamine after oral, intramuscular and transdermal administration of hondroxid maximum preparation in experiment]. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739190/),%,4.12,131099,DB01296,Glucosamine
,3164387,elimination half-lives,"The elimination half-lives were similar, 11.7 +/- 3.8 and 13.5 +/- 5.2 min, respectively (N.S.).",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,11.7,131990,DB01296,Glucosamine
,3164387,elimination half-lives,"The elimination half-lives were similar, 11.7 +/- 3.8 and 13.5 +/- 5.2 min, respectively (N.S.).",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,13.5,131991,DB01296,Glucosamine
,3164387,Cl,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],4.15,131992,DB01296,Glucosamine
,3164387,Cl,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],0.58,131993,DB01296,Glucosamine
,3164387,Vd,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],72.1,131994,DB01296,Glucosamine
,3164387,Vd,"The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],9.9,131995,DB01296,Glucosamine
,3164387,elimination half-life,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),min,69.0,131996,DB01296,Glucosamine
,3164387,Cl,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg·min],0.64,131997,DB01296,Glucosamine
,3164387,Vd,"We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg.",Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3164387/),[ml] / [kg],62.6,131998,DB01296,Glucosamine
,19695404,AUC(0-infinity),"The AUC(0-infinity) of the test and reference formulations was 1.83 (0.66) and 1.77 ( 0.72) microg/h/mL, respectively.","Bioequivalence of two formulations of glucosamine sulfate 500-mg capsules in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, fasting, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695404/),[μg] / [h·ml],1.83,136009,DB01296,Glucosamine
,19695404,AUC(0-infinity),"The AUC(0-infinity) of the test and reference formulations was 1.83 (0.66) and 1.77 ( 0.72) microg/h/mL, respectively.","Bioequivalence of two formulations of glucosamine sulfate 500-mg capsules in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, fasting, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695404/),[μg] / [h·ml],1.77,136010,DB01296,Glucosamine
,16145658,flow-rate,"Chromatographic separation was performed on a C(18) column (Inertsil ODS-3 150 x 2.1 mm i.d., 5 microm, JP) with a mobile phase gradient consisting of 0.2% acetic acid (aqueous) and methanol at a flow-rate of 0.3 mL/min.",Liquid chromatography with electrospray ionization mass spectrometry method for the assay of glucosamine sulfate in human plasma: validation and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16145658/),[ml] / [min],0.3,144737,DB01296,Glucosamine
,16145658,limit of detection,The limit of detection was 35 ng/mL for glucosamine sulfate in plasma and the linear range was 0.1-20 microg/mL in plasma with a correlation coefficient (r) of 0.9991.,Liquid chromatography with electrospray ionization mass spectrometry method for the assay of glucosamine sulfate in human plasma: validation and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16145658/),[ng] / [ml],35,144738,DB01296,Glucosamine
greater,16145658,Extraction recoveries,Extraction recoveries of glucosamine sulfate in plasma were greater than 73%.,Liquid chromatography with electrospray ionization mass spectrometry method for the assay of glucosamine sulfate in human plasma: validation and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16145658/),%,73,144739,DB01296,Glucosamine
,8267678,initial t1/2,"The results show that after i.v. administration the radioactivity due to glucosamine appears in plasma and is rapidly eliminated, with an initial t1/2 of 0.28 h.",Pharmacokinetics of glucosamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8267678/),h,0.28,150547,DB01296,Glucosamine
,8267678,t1/2,This radioactivity reaches a peak after 8-10 h and then declines with a t1/2 of 70 h.,Pharmacokinetics of glucosamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8267678/),h,70,150548,DB01296,Glucosamine
,6631692,se,The pharmacokinetics of intravenous I was described by a two-compartment body model with sequential plasma half-lives of 7.5 +/- 0.7 and 136 +/- 6 min.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),min,7.5,156777,DB01296,Glucosamine
,6631692,plasma half-lives,The pharmacokinetics of intravenous I was described by a two-compartment body model with sequential plasma half-lives of 7.5 +/- 0.7 and 136 +/- 6 min.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),min,7.5,156778,DB01296,Glucosamine
,6631692,plasma half-lives,The pharmacokinetics of intravenous I was described by a two-compartment body model with sequential plasma half-lives of 7.5 +/- 0.7 and 136 +/- 6 min.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),min,136,156779,DB01296,Glucosamine
,6631692,apparent volume of distribution of the central compartment,"The apparent volume of distribution of the central compartment, 13.1 +/- 0.7 liters, is approximately the volume of the total body water in a 20-kg dog.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),l,13.1,156780,DB01296,Glucosamine
,6631692,apparent overall volume of distribution,"The apparent overall volume of distribution of 40.0 +/- 1.5 liters exceeds the total body water, indicative of sequestration of I in tissues.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),l,40.0,156781,DB01296,Glucosamine
,6631692,Total,"Total and renal clearances were 205 +/- 5 and 155 +/- 5 ml/min, respectively.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),[ml] / [min],205,156782,DB01296,Glucosamine
,6631692,renal clearances,"Total and renal clearances were 205 +/- 5 and 155 +/- 5 ml/min, respectively.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),[ml] / [min],155,156783,DB01296,Glucosamine
less,6631692,Recovery of radioactivity,Recovery of radioactivity in the feces after I was intravenously administered was less than 1%.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),%,1,156784,DB01296,Glucosamine
less,6631692,Plasma protein binding,"Plasma protein binding of I was less than 5%, and the erythrocyte-plasma water partition coefficient was approximately unity.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),%,5,156785,DB01296,Glucosamine
,6631692,apparent partition coefficient,There was a readily chloroform-extractable metabolite with an apparent partition coefficient of 3.3 and Rf 0.43 on TLC in the systems used.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,3.3,156786,DB01296,Glucosamine
,6631692,Rf,There was a readily chloroform-extractable metabolite with an apparent partition coefficient of 3.3 and Rf 0.43 on TLC in the systems used.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,0.43,156787,DB01296,Glucosamine
,6631692,apparent partition coefficient,Ethyl acetate-extractable compounds (1.3-2.7%) had an apparent partition coefficient of 0.81 with Rf values of 0.52 and 0.68.,"Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,0.81,156788,DB01296,Glucosamine
,6631692,Rf,"Three unextractable compounds had Rf values of 0.20, 0.50, and 0.62 and accounted for 0.16, 2.8, and 0.9% of the administered radioactivity.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,0.20,156789,DB01296,Glucosamine
,6631692,Rf,"Three unextractable compounds had Rf values of 0.20, 0.50, and 0.62 and accounted for 0.16, 2.8, and 0.9% of the administered radioactivity.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,0.50,156790,DB01296,Glucosamine
,6631692,Rf,"Three unextractable compounds had Rf values of 0.20, 0.50, and 0.62 and accounted for 0.16, 2.8, and 0.9% of the administered radioactivity.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,0.62,156791,DB01296,Glucosamine
,6631692,Rf,"Three unextractable compounds had Rf values of 0.20, 0.50, and 0.62 and accounted for 0.16, 2.8, and 0.9% of the administered radioactivity.","Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631692/),,2,156792,DB01296,Glucosamine
,12214321,elimination t(1/2),"After the IV administration, glucosamine declined rapidly in a bi-exponential fashion with a mean (+/- S.D.) elimination t(1/2) of 0.52 (0.25) h.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),h,0.52,157989,DB01296,Glucosamine
,12214321,C(max),"GL absorption was relatively fast (C(max) = 8.95 microg/ml, and T(max) 1.5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),[μg] / [ml],8.95,157990,DB01296,Glucosamine
,12214321,T(max),"GL absorption was relatively fast (C(max) = 8.95 microg/ml, and T(max) 1.5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),h,1.5,157991,DB01296,Glucosamine
,12214321,bioavailability,"GL absorption was relatively fast (C(max) = 8.95 microg/ml, and T(max) 1.5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),%,12,157992,DB01296,Glucosamine
,12214321,C(max),The extent of absorption of chondroitin sulfate as indicated by the mean C(max) (21.5 microg/ml) and mean AUC (187 microg/ml h) of total disaccharides after dosing (1600 mg) provides evidence that chondroitin sulfate is absorbed orally.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),[μg] / [ml],21.5,157993,DB01296,Glucosamine
,12214321,AUC,The extent of absorption of chondroitin sulfate as indicated by the mean C(max) (21.5 microg/ml) and mean AUC (187 microg/ml h) of total disaccharides after dosing (1600 mg) provides evidence that chondroitin sulfate is absorbed orally.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),[μg] / [h·ml],187,157994,DB01296,Glucosamine
,12214321,bioavailability,The bioavailability of CS ranged from 4.8 to 5.0% after single dosing and 200-278% upon multiple dosing.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),%,4.8 to 5.0,157995,DB01296,Glucosamine
,12214321,bioavailability,The bioavailability of CS ranged from 4.8 to 5.0% after single dosing and 200-278% upon multiple dosing.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12214321/),%,200-278,157996,DB01296,Glucosamine
,15598026,C(max),"The C(max) of the powder-filled and timed release formulation (TimeOsamine) was 543.12 ng/ml and 520.98 ng/ml, respectively.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),[ng] / [ml],543.12,165949,DB01296,Glucosamine
,15598026,C(max),"The C(max) of the powder-filled and timed release formulation (TimeOsamine) was 543.12 ng/ml and 520.98 ng/ml, respectively.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),[ng] / [ml],520.98,165950,DB01296,Glucosamine
,15598026,t(max),"The t(max) of TimeOsamine was delayed by 4.13 h, whereas the powder-filled preparation was 1.00 h.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),h,4.13,165951,DB01296,Glucosamine
,15598026,t(max),"The t(max) of TimeOsamine was delayed by 4.13 h, whereas the powder-filled preparation was 1.00 h.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),h,1.00,165952,DB01296,Glucosamine
,15598026,AUC0-24,"The AUC0-24 of the 2 doses of TimeOsamine (2 x 500 mg = 1,000 mg) and the 3 doses of the powder-filled formulation (3 x 500 mg = 1,500 mg) was 6,263.32 ng x h/ml and 6,499.55 ng x h/ml, respectively.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),[h·ng] / [ml],"6,263.32",165953,DB01296,Glucosamine
,15598026,AUC0-24,"The AUC0-24 of the 2 doses of TimeOsamine (2 x 500 mg = 1,000 mg) and the 3 doses of the powder-filled formulation (3 x 500 mg = 1,500 mg) was 6,263.32 ng x h/ml and 6,499.55 ng x h/ml, respectively.","Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation--a multi-dose, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598026/),[h·ng] / [ml],"6,499.55",165954,DB01296,Glucosamine
,15797526,flow rate,"The mobile phase was a mixture of phosphate buffer (pH 7) and acetonitrile (80:20), which was run through a pump at a flow rate of 1.0 mL/min at ambient temperature.",High performance liquid chromatographic determination of N-butyryl glucosamine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15797526/),[ml] / [min],1.0,175604,DB01296,Glucosamine
,11642003,apparent half life,"Intravenous administration of CGS In man, after single bolus intravenous (i.v.) injection of 1005 mg CGS (628 mg Gl), the parent Gl disappears from plasma with an apparent half life of 1.11 h.","Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),h,1.11,178625,DB01296,Glucosamine
,11642003,lag time,Investigations with uniformly 14C labeled Gl (14C-Gl) administered with 502 mg CGS indicate that the disappearance of Gl is due to an incorporation into the plasma globulins that occurs with a lag time of 0.45 h and a rate of 0.26 h-1.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),h,0.45,178626,DB01296,Glucosamine
,11642003,rate,Investigations with uniformly 14C labeled Gl (14C-Gl) administered with 502 mg CGS indicate that the disappearance of Gl is due to an incorporation into the plasma globulins that occurs with a lag time of 0.45 h and a rate of 0.26 h-1.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),1/[h],0.26,178627,DB01296,Glucosamine
,11642003,t1/2,The radioactivity reaches a peak after 10 h and is eliminated with a t1/2 of 95 h.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),h,95,178628,DB01296,Glucosamine
,11642003,urinary excretion,"In man, after i.v. bolus injection of 1005 mg CGS, the urinary excretion in 24 h of Gl determined with ion exchange chromatography was 38% of the administered dose, mostly in the first 8 h after administration.","Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),,38,178629,DB01296,Glucosamine
,11642003,lag time,"After a single dose of 314 mg CGS traced with 14C-Gl, radioactivity appeared incorporated in plasma globulins with a lag time of 1.5 h and increasing with a rate of 0.24 h-1.","Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),h,1.5,178630,DB01296,Glucosamine
,11642003,rate,"After a single dose of 314 mg CGS traced with 14C-Gl, radioactivity appeared incorporated in plasma globulins with a lag time of 1.5 h and increasing with a rate of 0.24 h-1.","Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),1/[h],0.24,178631,DB01296,Glucosamine
,11642003,t1/2,The radioactivity then was eliminated with a t1/2 of 58 h.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),h,58,178632,DB01296,Glucosamine
,11642003,absolute oral bioavailability,The absolute oral bioavailability evaluated on the AUCs of the globulin-incorporated radioactivity was 44%.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),%,44,178633,DB01296,Glucosamine
,11642003,fecal excretion,The fecal excretion in 120 h was 11.3% of the administered dose showing that at least 88.7% of the administered dose was absorbed through the gastrointestinal tract.,"Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642003/),%,11.3,178634,DB01296,Glucosamine
higher,21310576,extraction recoveries,The extraction recoveries determined at three concentration levels were higher than 88.6%.,Application of a liquid chromatographic/tandem mass spectrometric method to a kinetic study of derivative glucosamine in healthy human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310576/),%,88.6,201409,DB01296,Glucosamine
,17580185,total gas flow,"Anesthesia was maintained with sevoflurane (2%), O(2), and N(2)O at a total gas flow of 6 L . min(-1) using a semiclosed circle system with a sodalime canister.",Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),[l] / [min],6,221315,DB01296,Glucosamine
,17580185,duration of surgery,Mean duration of surgery was 9:06 +/- 0:09 hours.,Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),h,9:06,221316,DB01296,Glucosamine
,19214525,VA,"In the glucosamine group, pain and functional outcomes statistically improved (VAS: 7.3 +/- 1.1 to 3.6 +/- 1.3, p < 0.001; AKS: 18.6 +/- 6.9 to 42.9 +/- 2.7, p < 0.01).",Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214525/),,3.,221437,DB01296,Glucosamine
,1656521,maximal blood glucose,The postprandial blood glucose increase after the müsli breakfast was significantly lower compared with the standard breakfast (maximal blood glucose 12.3 vs.,[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656521/),,12.3,223644,DB01296,Glucosamine
,1656521,AUC,"5.1 mml/l, AUC 360 vs, 468 mmol/l x min).",[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656521/),[mM] / [l·min],360,223645,DB01296,Glucosamine
,1656521,AUC,"5.1 mml/l, AUC 360 vs, 468 mmol/l x min).",[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656521/),[mM] / [l·min],468,223646,DB01296,Glucosamine
,1656521,AUC,"The blood glucose increase after the standard breakfast with miglitol was even lower (maximum 11.6 mmol/l, postprandial difference 2.9 mmol/l, AUC 241 mmol/l x min).",[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656521/),[mM] / [l·min],241,223647,DB01296,Glucosamine
,26808433,dose-normalized maximum plasma GS concentration,"However, the dose-normalized maximum plasma GS concentration was higher for the liquid supplement (5.5 ± 0.5 μg/mL) than for the two tablets (3.1 ± 0.6 and 2.1 ± 0.6 μg/mL, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),[μg] / [ml],5.5,225009,DB01296,Glucosamine
,26808433,dose-normalized maximum plasma GS concentration,"However, the dose-normalized maximum plasma GS concentration was higher for the liquid supplement (5.5 ± 0.5 μg/mL) than for the two tablets (3.1 ± 0.6 and 2.1 ± 0.6 μg/mL, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),[μg] / [ml],3.1,225010,DB01296,Glucosamine
,26808433,dose-normalized maximum plasma GS concentration,"However, the dose-normalized maximum plasma GS concentration was higher for the liquid supplement (5.5 ± 0.5 μg/mL) than for the two tablets (3.1 ± 0.6 and 2.1 ± 0.6 μg/mL, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),[μg] / [ml],2.1,225011,DB01296,Glucosamine
,26808433,time at which,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,0.7,225012,DB01296,Glucosamine
,26808433,time at which,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,4.2,225013,DB01296,Glucosamine
,26808433,time at which,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,5.0,225014,DB01296,Glucosamine
,26808433,maximal plasma GS concentrations occurred,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,0.7,225015,DB01296,Glucosamine
,26808433,maximal plasma GS concentrations occurred,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,4.2,225016,DB01296,Glucosamine
,26808433,maximal plasma GS concentrations occurred,"Similarly, the time at which maximal plasma GS concentrations occurred was shorter for the liquid formulation (0.7 ± 0.5 hr) than for the two tablets (4.2 ± 0.6 and 5.0 ± 0.6 hr, P < 0.001).","Comparison of Glucosamine Absorption After Administration of Oral Liquid, Chewable, and Tablet Formulations to Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808433/),h,5.0,225017,DB01296,Glucosamine
,4074405,urinary recovery,The compound is well eliminated by urinary route; the urinary recovery was 50% in 24 h and 67% 48 h after administration.,"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074405/),%,50,229377,DB01296,Glucosamine
,4074405,urinary recovery,The compound is well eliminated by urinary route; the urinary recovery was 50% in 24 h and 67% 48 h after administration.,"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074405/),%,67,229378,DB01296,Glucosamine
,15083499,C(max),GL was absorbed after oral dosing with a mean C(max) of 10.6 (6.9) microg/ml and a mean T(max) of 2.0 (0.7) h.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083499/),[μg] / [ml],10.6,232241,DB01296,Glucosamine
,15083499,T(max),GL was absorbed after oral dosing with a mean C(max) of 10.6 (6.9) microg/ml and a mean T(max) of 2.0 (0.7) h.,The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083499/),h,2.0,232242,DB01296,Glucosamine
,15083499,bioavailability,"However, the 16.9 kDa bioavailability was less than 8.0 kDa, but this difference was not significant.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083499/),k,16.9,232243,DB01296,Glucosamine
less,15083499,bioavailability,"However, the 16.9 kDa bioavailability was less than 8.0 kDa, but this difference was not significant.",The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083499/),kda,8.0,232244,DB01296,Glucosamine
,7086643,partition coefficient of I (pK'a,The partition coefficient of I (pK'a = 9.28) between chloroform and plasma was 6.4 +/- 0.2 SEM between pH 10.5 and 11.0.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),,9.28,241817,DB01296,Glucosamine
,7086643,partition coefficient of I (pK'a,The partition coefficient of I (pK'a = 9.28) between chloroform and plasma was 6.4 +/- 0.2 SEM between pH 10.5 and 11.0.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),,6.4,241818,DB01296,Glucosamine
,7086643,terminal half-life,The procedure was applied to pharmacokinetics in the dog and a two-compartment body model was observed with a terminal half-life of 103-130 min.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),min,103-130,241819,DB01296,Glucosamine
,7086643,renal clearances,The respective renal clearances of I were 135 and 163 ml/min.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),[ml] / [min],135,241820,DB01296,Glucosamine
,7086643,renal clearances,The respective renal clearances of I were 135 and 163 ml/min.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),[ml] / [min],163,241821,DB01296,Glucosamine
,7086643,total clearances,The respective total clearances of I were 204 and 191 ml/min.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),[ml] / [min],204,241822,DB01296,Glucosamine
,7086643,total clearances,The respective total clearances of I were 204 and 191 ml/min.,"Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086643/),[ml] / [min],191,241823,DB01296,Glucosamine
,2783183,half-lives of elimination,The half-lives of elimination varied between 6.63 and 11.9 h.,Tolerance and pharmacokinetics of a new antiulcer compound in man after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783183/),h,6.63 and 11.9,241898,DB01296,Glucosamine
,7175698,t1/2,"Pharmacokinetic studies in 10 volunteers (bolus i.v., 100 mg) showed respective half-lives for each exponential in the sum of two exponentials that characterized plasma level decay with time of 4.6 +/- 0.4 (SEM) min, t1/2(lambda 1), and 244 +/- 20 min, t1/2(lambda 2)), The total and renal clearances were 277 +/- 20 and 254 +/- 18 (SEM) ml/min, indicative of tubular secretion.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),min,244,244649,DB01296,Glucosamine
,7175698,t1/2,"Pharmacokinetic studies in 10 volunteers (bolus i.v., 100 mg) showed respective half-lives for each exponential in the sum of two exponentials that characterized plasma level decay with time of 4.6 +/- 0.4 (SEM) min, t1/2(lambda 1), and 244 +/- 20 min, t1/2(lambda 2)), The total and renal clearances were 277 +/- 20 and 254 +/- 18 (SEM) ml/min, indicative of tubular secretion.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),[ml] / [min],277,244650,DB01296,Glucosamine
,7175698,total,"Pharmacokinetic studies in 10 volunteers (bolus i.v., 100 mg) showed respective half-lives for each exponential in the sum of two exponentials that characterized plasma level decay with time of 4.6 +/- 0.4 (SEM) min, t1/2(lambda 1), and 244 +/- 20 min, t1/2(lambda 2)), The total and renal clearances were 277 +/- 20 and 254 +/- 18 (SEM) ml/min, indicative of tubular secretion.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),[ml] / [min],277,244651,DB01296,Glucosamine
,7175698,renal clearances,"Pharmacokinetic studies in 10 volunteers (bolus i.v., 100 mg) showed respective half-lives for each exponential in the sum of two exponentials that characterized plasma level decay with time of 4.6 +/- 0.4 (SEM) min, t1/2(lambda 1), and 244 +/- 20 min, t1/2(lambda 2)), The total and renal clearances were 277 +/- 20 and 254 +/- 18 (SEM) ml/min, indicative of tubular secretion.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),[ml] / [min],254,244652,DB01296,Glucosamine
,7175698,Urinary recovery,Urinary recovery was 93 +/- 2%.,"Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),%,93,244653,DB01296,Glucosamine
,7175698,volumes of distribution of the central compartment,"The estimated volumes of distribution of the central compartment and overall equilibrated tissues were 14.7 +/- 1.9 and 96 +/- 8 liters, respectively.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),l,14.7,244654,DB01296,Glucosamine
,7175698,volumes of distribution of the central compartment,"The estimated volumes of distribution of the central compartment and overall equilibrated tissues were 14.7 +/- 1.9 and 96 +/- 8 liters, respectively.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),l,96,244655,DB01296,Glucosamine
,7175698,bioavailability,"Sequential daily oral administration of large amounts in capsules (1.2, 2.1, 2.9, 4.1, and 5.0 g) permitted an estimate of 63 +/- 4 (SEM)% bioavailability from urinary recovery of drug, with estimated terminal half-lives of 454 +/- 25 min from minimal data.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),%,63,244656,DB01296,Glucosamine
,7175698,terminal half-lives,"Sequential daily oral administration of large amounts in capsules (1.2, 2.1, 2.9, 4.1, and 5.0 g) permitted an estimate of 63 +/- 4 (SEM)% bioavailability from urinary recovery of drug, with estimated terminal half-lives of 454 +/- 25 min from minimal data.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),min,454,244657,DB01296,Glucosamine
,7175698,t1/2,"Orally administered 2.03 g showed a rapid absorption (t1/2 = 10 min) after a lag time of 23 min, and a terminal plasma half-life of 344 min.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),min,10,244658,DB01296,Glucosamine
,7175698,lag time,"Orally administered 2.03 g showed a rapid absorption (t1/2 = 10 min) after a lag time of 23 min, and a terminal plasma half-life of 344 min.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),min,23,244659,DB01296,Glucosamine
,7175698,terminal plasma half-life,"Orally administered 2.03 g showed a rapid absorption (t1/2 = 10 min) after a lag time of 23 min, and a terminal plasma half-life of 344 min.","Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175698/),min,344,244660,DB01296,Glucosamine
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.40,245889,DB01296,Glucosamine
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.65,245890,DB01296,Glucosamine
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.95,245891,DB01296,Glucosamine
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,2.00,245892,DB01296,Glucosamine
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,3.50,245893,DB01296,Glucosamine
,17065354,half-life,"The half-life of plasma glucosamine after oral dosing was approximately 150 min, with no significant changes in steady-state glucosamine levels detectable after 6 weeks of therapy.",Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17065354/),min,150,249096,DB01296,Glucosamine
,18692410,maximal SF,The mean (+/-SD) maximal SF glucosamine levels (422.3+/-244.8 ng/mL) were significantly higher (>fourfold) in inflamed joints when compared to healthy joints (92.7+/-34.9 ng/mL).,Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18692410/),[ng] / [ml],422.3,252789,DB01296,Glucosamine
,18692410,maximal SF,The mean (+/-SD) maximal SF glucosamine levels (422.3+/-244.8 ng/mL) were significantly higher (>fourfold) in inflamed joints when compared to healthy joints (92.7+/-34.9 ng/mL).,Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18692410/),[ng] / [ml],92.7,252790,DB01296,Glucosamine
,18692410,glucosamine levels,The mean (+/-SD) maximal SF glucosamine levels (422.3+/-244.8 ng/mL) were significantly higher (>fourfold) in inflamed joints when compared to healthy joints (92.7+/-34.9 ng/mL).,Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18692410/),[ng] / [ml],422.3,252791,DB01296,Glucosamine
,18692410,glucosamine levels,The mean (+/-SD) maximal SF glucosamine levels (422.3+/-244.8 ng/mL) were significantly higher (>fourfold) in inflamed joints when compared to healthy joints (92.7+/-34.9 ng/mL).,Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18692410/),[ng] / [ml],92.7,252792,DB01296,Glucosamine
,28641925,half-life,Oral ManNAc was absorbed rapidly and exhibited a short half-life (~2.4h).,"Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28641925/),h,2.4,253690,DB01296,Glucosamine
,28641925,Tmax,"Following administration of a single dose of ManNAc, there was a significant and sustained increase in plasma unconjugated free sialic acid (Neu5Ac) (Tmax of 8-11h).","Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28641925/),h,8-11,253691,DB01296,Glucosamine
,19264438,limit of detection,"The limit of detection was 2.0 ng/ml, inter- and intra-day precision were less than 10%.",Determination of underivatized glucosamine in human plasma by high-performance liquid chromatography with electrochemical detection: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19264438/),[ng] / [ml],2.0,255136,DB01296,Glucosamine
,18295513,Plasma concentrations,Plasma concentrations reached approximately 50 microg/mL after i.v. injection and approximately 1 microg/mL after n.g. administration of both types of glucosamine.,Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295513/),[μg] / [ml],50,260705,DB01296,Glucosamine
,18295513,Plasma concentrations,Plasma concentrations reached approximately 50 microg/mL after i.v. injection and approximately 1 microg/mL after n.g. administration of both types of glucosamine.,Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295513/),[μg] / [ml],1,260706,DB01296,Glucosamine
,18295513,oral bioavailability,The median oral bioavailability was 9.4% for glucosamine sulphate and 6.1% for glucosamine hydrochloride.,Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295513/),%,9.4,260707,DB01296,Glucosamine
,18295513,oral bioavailability,The median oral bioavailability was 9.4% for glucosamine sulphate and 6.1% for glucosamine hydrochloride.,Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18295513/),%,6.1,260708,DB01296,Glucosamine
,11548224,Lequesne's index,The Lequesne's index was 10.6 +/- 0.45 S.E.M. points in both groups at the start of the study.,Glucosamine sulfate in osteoarthritis of the knee. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548224/),points,10.6,260709,DB01296,Glucosamine
,11548224,responder rate,The responder rate in the evaluable patients was 55% with glucosamine (N = 120) vs 38% with placebo (N = 121).,Glucosamine sulfate in osteoarthritis of the knee. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548224/),%,55,260710,DB01296,Glucosamine
,11548224,responder rate,The responder rate in the evaluable patients was 55% with glucosamine (N = 120) vs 38% with placebo (N = 121).,Glucosamine sulfate in osteoarthritis of the knee. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548224/),%,38,260711,DB01296,Glucosamine
,12207871,apparent terminal half-life,"After intravenous administration, the apparent terminal half-life (1.09 +/- 0.98 h), apparent steady state volume of distribution (2.1 +/- 1.1 L.kg(-1)) and total body clearance (2.61 +/- 0.81 L.kg(-1.h-1)) were calculated.",Single dose pharmacokinetics and bioavailability of glucosamine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207871/),h,1.09,272974,DB01296,Glucosamine
,12207871,apparent steady state volume of distribution,"After intravenous administration, the apparent terminal half-life (1.09 +/- 0.98 h), apparent steady state volume of distribution (2.1 +/- 1.1 L.kg(-1)) and total body clearance (2.61 +/- 0.81 L.kg(-1.h-1)) were calculated.",Single dose pharmacokinetics and bioavailability of glucosamine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207871/),[l] / [kg],2.1,272975,DB01296,Glucosamine
,12207871,total body clearance,"After intravenous administration, the apparent terminal half-life (1.09 +/- 0.98 h), apparent steady state volume of distribution (2.1 +/- 1.1 L.kg(-1)) and total body clearance (2.61 +/- 0.81 L.kg(-1.h-1)) were calculated.",Single dose pharmacokinetics and bioavailability of glucosamine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207871/),[l] / [h·kg],2.61,272976,DB01296,Glucosamine
,12207871,absolute bioavailability,"The peak plasma concentration, after oral administration, occurred approximately 30 min post-dose and the absolute bioavailability was 0.19.",Single dose pharmacokinetics and bioavailability of glucosamine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207871/),,0.19,272977,DB01296,Glucosamine
